Kintor Pharmaceutical Limited (KNTPF)
USD 0.16
(0.0%)
USD 0.16
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -191.57 Million CNY | 66.89% |
| 2022 | -578.69 Million CNY | 24.89% |
| 2021 | -770.41 Million CNY | 8.71% |
| 2020 | -843.88 Million CNY | -542.06% |
| 2019 | -131.43 Million CNY | -93.66% |
| 2018 | -67.87 Million CNY | -313.38% |
| 2017 | 31.8 Million CNY | 429.95% |
| 2016 | -9.63 Million CNY | 62.48% |
| 2015 | -25.69 Million CNY | -1173.55% |
| 2014 | -2.01 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -88.35 Million CNY | 53.88% |
| 2024 Q2 | -88.35 Million CNY | 5.09% |
| 2023 Q2 | -368.75 Million CNY | 1.12% |
| 2023 FY | -191.57 Million CNY | 66.89% |
| 2023 Q1 | -372.92 Million CNY | 35.56% |
| 2023 Q4 | -191.57 Million CNY | 2.31% |
| 2023 Q3 | -196.1 Million CNY | 46.82% |
| 2022 Q2 | -102.72 Million CNY | 4.81% |
| 2022 Q4 | -578.69 Million CNY | 0.76% |
| 2022 Q1 | -107.91 Million CNY | 85.99% |
| 2022 FY | -578.69 Million CNY | 24.89% |
| 2022 Q3 | -583.13 Million CNY | -467.64% |
| 2021 Q1 | -1.09 Billion CNY | -29.78% |
| 2021 FY | -770.41 Million CNY | 8.71% |
| 2021 Q4 | -770.41 Million CNY | 0.27% |
| 2021 Q3 | -772.48 Million CNY | 29.34% |
| 2021 Q2 | -1.09 Billion CNY | 0.18% |
| 2020 Q3 | -846.59 Million CNY | 46.42% |
| 2020 FY | -843.88 Million CNY | -542.06% |
| 2020 Q1 | -1.58 Billion CNY | -1104.42% |
| 2020 Q2 | -1.57 Billion CNY | 0.19% |
| 2020 Q4 | -843.88 Million CNY | 0.32% |
| 2019 Q4 | -131.43 Million CNY | 2.29% |
| 2019 Q1 | 138.05 Million CNY | 0.0% |
| 2019 FY | -131.43 Million CNY | -93.66% |
| 2019 Q3 | -134.52 Million CNY | 0.0% |
| 2018 FY | -67.87 Million CNY | -313.38% |
| 2017 Q3 | 31.8 Million CNY | 282.36% |
| 2017 FY | 31.8 Million CNY | 429.95% |
| 2017 Q1 | -17.44 Million CNY | -80.94% |
| 2017 Q2 | -17.44 Million CNY | 0.0% |
| 2017 Q4 | 31.8 Million CNY | 0.0% |
| 2016 Q4 | -9.63 Million CNY | 0.0% |
| 2016 FY | -9.63 Million CNY | 62.48% |
| 2016 Q1 | -25.51 Million CNY | 0.0% |
| 2016 Q3 | -9.63 Million CNY | 0.0% |
| 2015 FY | -25.69 Million CNY | -1173.55% |
| 2014 FY | -2.01 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 1315.371% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 4752.207% |
| SQZ Biotechnologies Company | -36.23 Million USD | -428.669% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 547.688% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -2938.754% |
| Mesoblast Limited | 55.85 Million USD | 442.973% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 20762.413% |
| Genus plc | 190.6 Million USD | 200.514% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 8668.578% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 15882.263% |
| Marizyme, Inc. | 18.56 Million USD | 1131.713% |
| ContraFect Corporation | -6.02 Million USD | -3079.207% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 28273.382% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 142390.867% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 16680.768% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 8644.117% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 3582.054% |
| MultiCell Technologies, Inc. | 90.04 USD | 212771090.671% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -26001.464% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 1579.832% |
| EV Biologics, Inc. | 1.36 Million USD | 14104.61% |
| Q BioMed Inc. | 4.06 Million USD | 4818.685% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 727.018% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 30882.468% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 19111.21% |
| Biomind Labs Inc. | 711.4 Thousand USD | 27029.781% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 274.474% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 1595.941% |
| Skye Bioscience, Inc. | -5.72 Million USD | -3248.47% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 22370.387% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 137133.99% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 3491.757% |
| IMV Inc. | 7.67 Million USD | 2597.601% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 964407.646% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 8800.302% |
| GB Sciences, Inc. | 1.74 Million USD | 11064.187% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -104139.123% |
| HST Global, Inc. | 96.79 Thousand USD | 198026.503% |
| CSL Limited | 10.52 Billion USD | 101.82% |
| Halberd Corporation | 144.72 Thousand USD | 132478.162% |
| Enzolytics Inc. | 981.65 Thousand USD | 19615.9% |
| Resverlogix Corp. | 6.45 Million USD | 3069.757% |
| Affymax, Inc. | -5.59 Million USD | -3322.887% |
| SYBLEU INC | 473.71 Thousand USD | 40541.912% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -28362.655% |
| argenx SE | -2.02 Billion USD | 90.557% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 541.081% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -307.511% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 7172.951% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -2067.205% |
| AVAX Technologies, Inc. | -5.9 Million USD | -3145.338% |
| Zenith Capital Corp. | 10.06 Thousand USD | 1903706.916% |
| Genscript Biotech Corporation | -1.06 Billion USD | 81.949% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 95683.041% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 8129.181% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 116555.027% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 416.42% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 9681.863% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -7354.343% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 53359.292% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 1044.856% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -1045751.075% |
| BioStem Technologies, Inc. | 4.47 Million USD | 4383.956% |
| ONE Bio Corp. | 9.04 Million USD | 2219.229% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 95292.642% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -14624251.145% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 93001.652% |
| Agentix Corp. | 37.63 Thousand USD | 509198.881% |
| LadRx Corporation | -2.03 Million USD | -9307.411% |
| Cell Source, Inc. | 9.23 Million USD | 2175.169% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -938644.61% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 30261.989% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 30261.989% |
| NovAccess Global Inc. | 2.17 Million USD | 8894.22% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 2809.373% |
| Itoco Inc. | 228.3 Thousand USD | 84013.624% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 140978.306% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 3964.817% |
| Kadimastem Ltd | -253.1 Thousand USD | -75592.409% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 47774.375% |
| CytoDyn Inc. | 20.26 Million USD | 1045.509% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -29610255.487% |
| Mobile Lads Corp. | 484.23 Thousand USD | 39663.474% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -2066926.026% |
| Qrons Inc. | 351.42 Thousand USD | 54614.593% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 2586.101% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -76648.257% |
| Rebus Holdings, Inc. | 305 Thousand USD | 62912.787% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 4398.363% |
| International Stem Cell Corporation | 2.59 Million USD | 7496.873% |
| Bioxytran, Inc. | 1.89 Million USD | 10188.872% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 307053.68% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 8884.401% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 5678.888% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 2339.904% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 24896.436% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -15226.32% |
| Neutra Corp. | 52.18 Thousand USD | 367201.002% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -7597.027% |
| PureTech Health plc | -167.19 Million USD | -14.583% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -78124.884% |
| IXICO plc | -4.44 Million USD | -4210.389% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 1549.27% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 449.272% |
| CSL Limited | 10.52 Billion USD | 101.82% |
| Cellectis S.A. | -43.81 Million USD | -337.207% |